289 results on '"George, Lindsey A."'
Search Results
2. Roctavian gene therapy for hemophilia A
3. Coagulation factor VIII: biological basis of emerging hemophilia A therapies
4. Coagulation factor VIII regulates von Willebrand factor homeostasis invivo
5. Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells
6. Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis
7. Overcoming Hemophilia A Gene Therapy Limitations with an Enhanced Function Factor VIII Variant
8. Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX‐Padua
9. Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab
10. Coagulation Cascade and Fibrinolysis Pathway: Assessment in the Laboratory
11. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial
12. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding
13. Hemophilia A Gene Therapy — Some Answers, More Questions
14. Retraction notice to "Maternal Nutrient Restriction Predisposes Ventricular Remodeling in Adult Sheep Offspring" [The Journal of Nutritional Biochemistry 24 (2013) 1258-1265]
15. Adeno-Associated Virus Gene Therapy for Hemophilia
16. Oyster reef restoration: effect of alternative substrates on oyster recruitment and nekton habitat use
17. Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011
18. Factor VIII Mimetic Rescue of Hemophilia B Causing Factor IX Variants
19. Inhibiting Activated Protein C Cleavage of Factor VIII for Hemophilia a Gene Therapy
20. Antigen Trafficking and Possibly Intrinsic Immunostimulatory Properties Shape High Immunogenicity of Factor VIII
21. Coagulation Factor VIII Enhances the Cleavage of Von Willebrand Factor By ADAMTS13 In Vivo
22. Total Knee Arthroplasty after Gene Therapy for Hemophilia B
23. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
24. Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children
25. Factor IX Padua for haemophilia B gene addition: universal adaptation and repeated success
26. Design and Benchmarking of a Network-In-the-Loop Simulation for Use in a Hardware-In-the-Loop System
27. Plain language summary for the manuscript: Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua
28. Hemophilia gene therapy: ushering in a new treatment paradigm?
29. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A
30. Follow-up of More Than 5 Years in a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec Adeno-Associated Virus Gene Therapy
31. Haemophilia care: the only constant is change
32. Health-Related Quality of Life in Adults with Hemophilia B after Receiving Gene Therapy with Fidanacogene Elaparvovec
33. The Mercury Emergency and Hamilton School Children: A Follow-up Analysis
34. The Mercury Emergency in Hamilton, September 1993
35. Fidelity and Recovery-Orientation in Assertive Community Treatment
36. System-Wide Implementation of ACT in Ontario: An Ongoing Improvement Effort
37. Activated protein C has a regulatory role in factor VIII function
38. Housing Choice and Control, Housing Quality, and Control over Professional Support as Contributors to the Subjective Quality of Life and Community Adaptation of People with Severe Mental Illness
39. Housing for people with serious mental illness: challenges for system-level community development
40. No CpGs for AAVs?
41. Current Clinical Applications of In Vivo Gene Therapy with AAVs
42. Current Developments in Assertive Community Treatment
43. Recovery-Oriented Service Provision and Clinical Outcomes in Assertive Community Treatment
44. Surrogate Estimates of Insulin Sensitivity in Obese Youth along the Spectrum of Glucose Tolerance from Normal to Prediabetes to Diabetes
45. Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH
46. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B
47. Combined anti‐CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors
48. On certain cases of poisoning
49. Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year
50. In Vivo hemostatic Significance of Activated Protein C in Factor VIIIa Regulation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.